# Percutaneous Orthotopic Transcatheter Tricuspid Valve Replacement for Native Valve Destruction After Endocarditis

## TL;DR

A new transcatheter method successfully treats severe tricuspid valve damage in a high-risk patient, offering a promising alternative to surgery.

## Contribution

Presents a novel transcatheter tricuspid valve replacement technique for patients with extensive valve destruction.

## Key findings

- Orthotopic TTVR using the LuX-Valve Plus system improved clinical outcomes in a patient with severe TR and leaflet destruction.
- The LuX-Valve Plus features enable stability and right ventricular function preservation in complex anatomies.
- Multimodality imaging is critical for successful procedural planning in TTVR.

## Abstract

Transcatheter tricuspid valve replacement (TTVR) is emerging as an option for treating severe tricuspid regurgitation (TR) in patients at high surgical risk.

A 59-year-old man with torrential TR and right heart failure following Staphylococcus aureus tricuspid valve infective endocarditis and extensive leaflet destruction was successfully treated with orthotopic TTVR using the LuX-Valve Plus system (Jenscare), resulting in significant clinical improvement and favorable right ventricular remodeling.

The LuX-Valve Plus, delivered via transjugular access, enables optimal coaxial alignment during deployment. Its unique features—leaflet graspers, a septal anchoring mechanism, and a flexible frame—provide stability and preserve right ventricular function, making it suitable for complex tricuspid anatomies.

Orthotopic TTVR with the LuX-Valve Plus offers a viable option for patients with severe TR and extensive leaflet destruction, previously considered ineligible for surgical or transcatheter repair. Multimodality imaging is essential for procedural planning and optimal outcomes.